Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 12Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3

Conditions

Breast Neoplasms 1320Neoplasms 983Carcinoma, Non-Small-Cell Lung 858Prostatic Neoplasms 723Colorectal Neoplasms 662Lung Neoplasms 548Leukemia, Myeloid, Acute 475Neoplasm Metastasis 431Pancreatic Neoplasms 418Carcinoma, Hepatocellular 406Multiple Myeloma 397Ovarian Neoplasms 391Stomach Neoplasms 378Recurrence 365Squamous Cell Carcinoma of Head and Neck 325Melanoma 293Brain Neoplasms 287Uterine Cervical Neoplasms 283Triple Negative Breast Neoplasms 271Head and Neck Neoplasms 263Glioblastoma 263Precursor Cell Lymphoblastic Leukemia-Lymphoma 254Endometrial Neoplasms 233Lymphoma 227Esophageal Neoplasms 222Rectal Neoplasms 221Sarcoma 211Carcinoma, Renal Cell 203Colonic Neoplasms 193Lymphoma, Large B-Cell, Diffuse 191

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Vascular Diseases × Clear all
NCT07075185 2026-04-24

inMMyCAR

Kelonia Therapeutics, Inc.

Phase 1 Recruiting
70 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Shenzhen University General Hospital

Phase 1/2 Recruiting
10 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

OriCell Therapeutics Co., Ltd.

Phase 1 Recruiting
81 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡